Non-small Cell Lung Cancer Stage I Clinical Trial
— IMPLANE-0529Official title:
Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane: A Multicenter、Prospective、Randomized Controlled Trial
This study is a multi-center, prospective, randomized controlled clinical trial. The purpose is to compare the difference of indocyanine green fluorescence imaging method and modified inflation-deflation method in identifying intersegmental plane in segmentectomy, and provide high-level evidence for the selection of intersegmental plane identification method in early NSCLC segmental resection.
Status | Recruiting |
Enrollment | 272 |
Est. completion date | December 31, 2027 |
Est. primary completion date | July 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Aged 18 to 80 years old; 2. According to the surgical standards of the Eighth edition of People's Medical Publishing House, patients whose blood pressure was under 160/100mmHg and blood glucose was under 5.6-11.2mmol /L with normal functions of major organs such as heart, lung, liver and kidney before surgery are included. The main criteria are as follows: i. Cardiac function examination indicated Goldman index grade 1-2; ii. Pulmonary function examination suggested postoperative predicted FEV1=40% and DLCO=40%; iii. Total bilirubin =1.5 times the upper limit of normal; iv. Alanine aminotransferase and aspartate aminotransferase =2.5 times the upper limit of normal value; v. Creatinine =1.25 times the upper limit of normal value and creatinine clearance =60ml/min; 3. The center of the lesion is located in the other lobes except the middle lobe, and in the middle and outer third of the lung; 4. The maximum diameter of the tumor was not more than 2cm on TLC(Thin layer CT) scan and the clinical stage was cT1a-1bN0M0(according to AJCC staging criteria, eighth edition); 5. Consolidation tumor rate <1; 6. ECOG PSscore 0-1; 7. All relevant examinations should be completed within 28 days before surgery; 8. Patients who understand the study and have signed informed consent. Exclusion Criteria: 1. Patient with a history of iodine or indocyanine green allergy; 2. Patient who had received antitumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) prior to surgery; 3. Patient with a history of other malignancies; 4. Patient with secondary primary cancer at enrollment; 5. Small cell lung cancer; 6. Prior history of unilateral thoracotomy; 7. Woman in pregnant or breastfeeding period; 8. Patient with interstitial pneumonia, pulmonary fibrosis or severe emphysema; 9. An active bacterial or fungal infection that is difficult to control; 10. Severe mental illness; 11. History of severe heart disease , heart failure , myocardial infarction or angina pectoris within the last 6 months; 12. patient that researcher considers inappropriate to participate in this study. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Nanchang University | Dazhou Central Hospital, First Affiliated Hospital of Gannan Medical University, Fuzhou Pulmonary Hospital of Fujian, Guangdong Provincial People's Hospital, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningde Municipal Hospital of Ningde Normal University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Wuhan Union Hospital, China, Zhejiang Provincial People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Coincidence rate of intersegmental plane identification | The shortest distance between the nodule and the cutting edge in all directions in postoperative pathological specimens versus distances measured in preoperative 3D reconstruction in same directions | Within 14 days after surgery | |
Primary | Success rate of intersegmental plane identification | Successful intraoperative appearance of the intersegmental plane is considered a success | During the operation | |
Secondary | Intersegment plane identification time | Indocyanine green injection/start of ventilation to the first observed intersegment plane appearance | During the surgery | |
Secondary | Surgery time | Time from the beginning to the end of the surgery | During the surgery | |
Secondary | Intraoperatve blood loss | Blood loss during the surgery | During the surgery | |
Secondary | Postoperative blood loss | Blood loss after the surgery | Postoperative in-hospital stay up to 30 days | |
Secondary | Postoperative air leakage rate | Air leakage after the surgery | Postoperative in-hospital stay up to 30 days | |
Secondary | Postoperative air leakage time | time of air leakage after the surgery | Postoperative in-hospital stay up to 30 days | |
Secondary | Preoperative pulmonary function | FEV1.0(forced expiratory volume in 1.0 s) | 1 week before the surgery | |
Secondary | Preoperative pulmonary function | FVC(forced vital capacity) | 1 week before the surgery | |
Secondary | Postoperative pulmonary function | FEV1.0(forced expiratory volume in 1.0 s) | 6/12 months after surgery | |
Secondary | Postoperative pulmonary function | FVC(forced vital capacity) | 6/12 months after surgery | |
Secondary | Quality of life(EORTCQLQ-C30) | Quality of life Scale | 6/12 months after surgery | |
Secondary | Adverse event rate | According to CTCAE-V5.0 | Through study completion, an average of 2 year | |
Secondary | Adverse event level | According to CTCAE-V5.0 | Through study completion, an average of 2 year | |
Secondary | Surgical complication | According to Clavien-Dindo grading system | Postoperative in-hospital stay up to 30 days | |
Secondary | Postoperative 30-day mortality | Deaths occurring within 30 days after surgery | Within 30 days after surgery | |
Secondary | Postoperative 90-day mortality | Deaths occurring within 90 days after surgery | Within 90 days after surgery | |
Secondary | Reoperation rate | The percentage of patients who need a second operation | Within 30 days after surgery | |
Secondary | Number of stapler nail bin used for cutting | Number of stapler nail bin used for cutting | During the surgery | |
Secondary | R0 resection rate | Negative surgical margin under the microscope | Within 14 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03603002 -
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
|
N/A | |
Completed |
NCT04342377 -
The Canada Lymph Node Score Project: A Crossover Trial
|
Phase 3 | |
Recruiting |
NCT05097417 -
Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
|
N/A | |
Recruiting |
NCT06341387 -
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
|
||
Completed |
NCT01991418 -
Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
|
N/A | |
Completed |
NCT03216551 -
Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
|
||
Recruiting |
NCT03172156 -
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
|
N/A | |
Withdrawn |
NCT03431415 -
Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer
|
N/A | |
Recruiting |
NCT04716946 -
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
|
Phase 2 | |
Withdrawn |
NCT03029871 -
Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT06180239 -
Segmentectomy vs Lobectomy
|
||
Active, not recruiting |
NCT03383302 -
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
|
Phase 1/Phase 2 | |
Completed |
NCT04271384 -
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT02622581 -
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
|
||
Not yet recruiting |
NCT02011997 -
Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
|
Phase 3 | |
Active, not recruiting |
NCT01795521 -
LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC
|
Phase 2 | |
Recruiting |
NCT04944173 -
SCION: SABR and Checkpoint Inhibition Of NSCLC
|
Phase 2 | |
Recruiting |
NCT04585477 -
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
|
Phase 2 |